Clinical Trial

A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 19, 2024 (before its estimated May 2025 completion). Its status may not reflect the trial's current state.
Summary
A study to investigate the safety, tolerability, and pharmacokinetics of a SARS-CoV-2-directed monoclonal antibody in healthy participants
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-07-22; most recent amendment 2024-11-15.
Status change: Recruiting → Active, Not Recruiting 2024-11-15
Status change: Not Yet Recruiting → Recruiting 2024-09-20
Trial Details
NCT Number NCT06523153
Lead Sponsor Invivyd, Inc.
Collaborators: Novotech (Australia) Pty Limited
Conditions COVID-19
Enrollment 40 participants
Start Date 2024-08-28
Primary Completion 2025-05 (estimated)
Study Completion 2025-05 (estimated)
Updated on ClinicalTrials.gov 2024-11-19